RBX2630

Name: RBX2660
Synonyms: RBX 2660
Indication: Clostridium difficile Prevention
Company: Rebiotix ; Rebiotix (Ferring Pharmaceuticals Group)

Rebiotix (is a subsidiary of Ferring Pharmaceuticals) is developing RBX 2660, a biological product. Rebiotix's RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world's first approved human microbiome product.
CDI is one of the most common healthcare-associated infections in the US, affecting more than 500,000 people and causing approximately 29,000 deaths each year. Ferring's global capabilities ensure broader patient access to any future approved human microbiome treatments derived from Rebiotix's Microbiota Restoration Therapy™ (MRT™) drug platform.

RBX2660 has the potential to be the first human microbiome product approved anywhere in the world. In the US, RBX2660 has received FDA Fast Track, Breakthrough Therapy and Orphan Drug Designations, which means the FDA considers it eligible for Expedited Review, once the submission has been made.

The first formulation of the platform, RBX2660, is currently in clinical trials for the prevention of recurrent Clostridium difficile (C. diff) infection. The clinical trials are conducted under the U.S. FDA's Investigational New Drug (IND) application with the purpose of studying safety, efficacy, and impact of microbiota-based therapeutics' on the prevention of C. diff recurrence. The second formulation in development, RBX7455, is the first of its kind non-frozen, room-temperature stable, orally delivered microbiota-based product. RBX2660 and RBX7455 will serve as critical facets of the MRT drug platform, paving the way for further research and product development. Currently, the MRT drug platform is the most clinically advanced program in the world.